Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Crohn's Disease Patients

A study in the March 2015 issue of CGH finds that withdrawal of immunomodulators after at least 6 months of co-treatment with infliximab does not reduce the trough levels of infliximab in patients with Crohn's disease.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: podcasts